Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: A crossover open-label study of five drug regimens

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 304-310

  Farshi, Ramin ^a,b   Kistner, Deborah ^a,b   Sarma, Jonnalagedda S M ^a,b   Longmate, Jeffrey A ^a,b   Singh, Bramah N ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; DIGOXIN; DILTIAZEM;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DAILY LIFE ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; EXERCISE; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MALE; PRIORITY JOURNAL;

AGED; ANTI-ARRHYTHMIA AGENTS; ATENOLOL; ATRIAL FIBRILLATION; CALCIUM CHANNEL BLOCKERS; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIGOXIN; DILTIAZEM; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY, AMBULATORY; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HEART VENTRICLES; HUMANS; MALE; MIDDLE AGED;

EID: 0033081953     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00561-0     Document Type: Article

References (33)

1. Feinberg W.M., Blackshear J.L., Laupacis A., Kronmal R., Hart R.G. Prevalence, age distribution, and gender of patients with atral fibrillation Analysis and implications. Arch Intern Med. 13:1995;469-473.
2. Wolf P.A., Mitchell J.B., Baker C.S., Kannel W.B., D'Agostino R.B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 158:1998;229-234.
3. Murgatroyd F.D., Camm A.J. Atrial arrhythmias. Lancet. 341:1993;1317-1322.
4. Grogan M., Smith H.C., Gersh B.J., Wood D.L. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol. 69:1992;1570-1573.
5. Cairns J.A., Conolly S.J. Nonrheumatic atrial fibrillation risk of stroke and role of antithrombotic therapy . Circulation. 84:1991;469-481.
6. Van Gelder I.C., Crijns H.J., Blanksma P.K., et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with chronic valve disease. Am J Cardiol. 72:1993;560-566.
7. Singer D.E. Randomized trials of warfarin for atrial fibrilation. New Eng J Med. 327:1992;1451-1453.
8. Rawles J.M. What is meant by "controlled" ventricular rate in atrial fibrillation. Br Heart J. 63:1990;157-161.
9. Yahalom J., Klein H.O., Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest. 71:1977;592-596.
10. Klein H.O., Pauzner H., Di Segni E., David D., Kaplinsky E. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med. 139:1979;747-749.
11. David D., Di Segni E., Klein H.O., Kaplinsky E. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation beneficial effects of an added beta-adrenergic blocking agent. Am J Cardiol. 44:1979;1378-1382.
12. Redfors A. Plasma digoxin concentration - its relation to digoxin and clinical effects in patients with atrial fibrillation. Br Heart J. 34:1972;383-391.
13. Beasley R., Smith D.A., McHaffie D.J. Exercise heart rates at different serum digoxin concentrations in patients with atrial fibrillation. Br Med J. 290:1985;9-11.
14. Steinberg J., Katz R., Bren G., et al. Efficacy of oral diltiazem to control ventricular response in chronic atrial fibrillation at rest and during exercise. J Am Coll Cardiol. 9:1987;405-411.
15. Maragno I., Santostasi G., Gaion R.M., et al. Low- and medium-dose diltiazem in chronic atrial fibrillation comparison with digoxin and correlation with drug plasma levels. Am Heart J. 116:1988;385-392.
16. Atwood J.E., Myers J.N., Sullivan M.J., et al. Diltiazem and exercise performance in chronic atrial fibrillation. Chest. 93:1988;20-25.
17. Lang R., Klein H.O., Weiss E., et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest. 83:1983;491-499.
18. Lundstrom T., Ryden L. Ventricular rate control and exercise performance in chronic atrial fibrillation effects of diltiazem and verapamil. J Am Coll Cardiol. 16:1990;86-90.
19. Klein H.O., Kaplinsky E. Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent? Drugs. 31:1986;185-197.
20. Pomfret S., Beasley C.R., Challenor V., Holgate S.T. Relative efficacy of oral verapamil and digoxin alone and in combination for the treatment of patients with chronic atrial fibrillation. Clin Sci. 74:1988;351-357.
21. Lewis R., Irvine N., McDevitt K. Relationships between heart rate, exercise tolerance and cardiac output in atrial fibrillation the effects of treatment with digoxin, verapamil and diltiazem. Eur Heart J. 9:1988;777-781.
22. DiBianco R., Morganroth J., Freitag R.J., Ronan J.A. Jr. Effects of nadolol on the spontaneous and exercise-provoked heart rate in patients with chronic atrial fibrillation receiving stable doses of digoxin. Am Heart J. 108:1984;1121-1127.
23. Roth A., Harrison E., Mitani G., et al. Efficacy and safety of medium- and high-dose diltiazem alone and in combination with digoxin for control of heart rate at rest and during exercise in patients with chronic atrial fibrillation. Circulation. 73:1986;316-324.
24. Molajo A.O., Coupe M., Bennett D. Effect of Corwin (ICI 118587) on resting and exercise heart rate and exercise tolerance in digitilised patients with chronic atrial fibrillation. Br Heart J. 52:1984;392-395.
25. Zarowitz B.J., Gheorghiade M. Optimal heart rate control for patients with chronic atrial fibrillation Are pharmacologic choices truly changing? Am Heart J. 123:1992;1401-1403.
26. Lanas F., Salvatici R., Castillo G., Montecinos A., Stockins B., Molnar J. Comparison between digoxin and atenolol in chronic atrial fibrillation. Rev Med Chil. 123:1995;1252-1262.
27. Krauchi K., Cajochen C., Mori D., Graw A.T., Wirz-Justice A. Early evening melotonin and S20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol. 272:1997;R1178-R1188.
28. Nelson W., Tong Y.L., Lee J.K., Halberg F. Methods for cosinor-rhythmometry. Chronobiologia. 6:1979;305-323.
29. Rodin S.M., Johnson B.F. Pharmacokinetic interactions with digoxin. Clin Pharmacokinet. 15:1988;227-244.
30. Bala Subramanian V. Clinical and research applications of ambulatory Holter ST segment and heart rate monitoring. Am J Cardiol. 58:1986;11B-20B.
31. Lang R., Klein H.O., Di Segni E., et al. Verapamil improves exercise capacity in chronic atrial fibrillation double blind crossover study. Am Heart J. 105:1983;820-825.
32. Packer D.L., Bardy G.H., Worley S.J., et al. Tachycardia-induced cardiomyopathy a reversible form of left ventricular dysfunction. Am J Cardiol. 57:1986;563-570.
33. Rodriguez L.M., Smeets J.L.R.M., Xie B., et al. Improvement in left ventricular function by ablation of atrioventricular nodal conduction in selected patients with lone atrial fibrillation. Am J Cardiol. 72:1993;1137-1141.